Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
Status:
Terminated
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the
safety, pharmacokinetics, and pharmacodynamics of 12 weeks' administration of SGM-1019 in
subjects with fibrosis stage 1-3 (F1-F3) NASH.